首页|老年慢病管理之降脂药物与药物基因组学研究和应用进展

老年慢病管理之降脂药物与药物基因组学研究和应用进展

扫码查看
降脂药物是目前全球公认的血脂异常治疗基石,但降脂药物的疗效和不良反应存在个体差异,其中药物基因组学是造成这种差异的主要原因之一.为了更加全面了解降脂药物基因组学,指导临床降脂药物选择,为提高老年人群临床降脂疗效、减少毒副作用提供参考,根据国内外相关文献和资料,对临床常用的他汀类药物、贝特类药物、烟酸类药物、依折麦布和PCSK9抑制剂的临床治疗进展、药物基因组学技术及研究应用进展进行综述.现有研究已经证明药物基因可以为降脂精准治疗提供参考,但费用以及对药物基因组学的知识普及不够等因素,限制了药物基因组学在临床中的应用.未来宜逐渐加强药物基因组学的临床研究及知识普及,推动我国精准医学的快速发展.
Research and Application Progress of Lipid-Lowering Drugs and Pharmacogenomics in Chronic Disease Management of Older People
Lipid-lowering drugs are currently recognized as the cornerstone in treating dyslipidemia.However,there are individual differences in terms of the efficacy and adverse reactions of lipid-lowering drugs,and pharmacogenomics is one of the main reasons for this difference.In order to have a more comprehensive understanding of lipid-lowering pharmacogenomics,guide the selection of lipid-lowering drugs,and provide references for improving clinical lipid-lowering efficacy and reducing toxic and side effects among the elderly population,based on the relevant literature and data at home and abroad,this paper reviewed the clinical treatment progress,pharmacogenomic technologies and application progress of statins,fibrates,niacin,ezetimibe and PCSK9 inhibitors commonly used in clinical practice.Existing studies have proved that pharmacogenomics can provide a reference for lipid-lowering precision therapy,but the clinical application of pharmacogenomics is limited due to the high cost and insufficient knowledge about pharmacogenomics.In the future,we should gradually strengthen the clinical research and knowledge popularization of pharmacogenomics to promote the rapid development of precision medicine in China.

management of chronic diseases among the elderlylipid-lowering drugspharmacogenomicsgenetic polymorphism

廖蓉

展开 >

重庆医科大学附属第一医院第一分院,重庆 400010

老年慢病管理 降脂药物 药物基因组学 基因多态性

2024

老龄科学研究

老龄科学研究

影响因子:0.965
ISSN:
年,卷(期):2024.12(6)